Prevalence and Severity of Sensorineural Hearing Loss in Diabetic and Hypertensive Patients: A Comparative Cross-Sectional Study.

Background The ability to perceive sound is crucial for effective communication and environmental awareness. This study aimed to assess sensorineural hearing loss (SNHL) in patients with both diabetes mellitus (DM) and hypertension (HTN). Materials and methods A total of 120 participants of both genders were divided into three groups: Group I consisted of diabetic patients (n=40, 22 males and 18 females), Group II included hypertensive individuals (n=40, 16 males and 24 females), and Group III served as controls (n=40, 15 males and 25 females). General ear examinations, including otoscopy, were conducted. Hearing function and the degree, pattern, and configuration of hearing loss were assessed using general ear examinations and pure tone audiometry. Results Normal hearing was observed in 25% of Group I, 26% of Group II, and 85% of Group III. Mild hearing loss was evident in 75% of Group I, 50% of Group II, and 15% of Group III, while moderate hearing loss was observed in 24% of Group II. These differences were statistically significant (P < 0.05). Conclusion Diabetic and hypertensive individuals demonstrated a higher hearing loss prevalence than healthy controls.

Pulmonary Hypertension in Scleroderma- Evaluation and Management.

Pulmonary Arterial Hypertension (PAH) is a clinical syndrome consisting of physiologic/hemodynamic criteria that are a consequence of several etiologies. Systemic Sclerosis (SSc), one of the most common causes of PAH, is an autoimmune disorder of the connective tissue leading to fibrosis that involves the skin, gastrointestinal tract, lungs, heart, kidney etc. SSc has an annual prevalence of one to five cases for every 1000 individuals and nearly 15 percent of all cases develop PAH. At its core, Pulmonary hypertension (PH) in SSc is an obliterative vasculopathy in small to medium-sized pulmonary arterioles. A host of other local and systemic mechanisms operate in concert to gradually alter the hemodynamics resulting in elevated pulmonary vascular resistance and thus right ventricular afterload. A diagnosis of PAH in SSc is virtually a death sentence, with studies reporting a mortality rate of 50 per cent in the 3 years of diagnosis. Therefore, developing and implementing a robust screening and diagnosis protocol is crucial in the fight against this pervasive disease. This review aims to summarize the current literature of PAH in SSc, with a special focus on the screening and diagnosis protocols, newer treatment options and prognostic indicators for the same.